Author:
Montero Silvia Sánchez,Guix Elena Monfa,Ausín Monica Sierra,García Francisco Izquierdo,Gómez Benjamin León,Martinez-Rosero Caterine Vanesa,Guerrero Xhamy Yosue Martelli,Zaldumbide Erika Jenelia Romero,Velasco Mario Alfredo Prieto,Alvarez Cristina Lucas,Lopez Aranzazu Sastre,Kasabji George Estifan
Reference5 articles.
1. Biologics and targeted synthetic drugs can induce immune-mediated glomerular disorders in patients with rheumatic diseases: an updated systematic literature review;Chessa;BioDrugs.,2021
2. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis;Stokes;Nephrol Dial Transplant.,2005
3. Crohn disease complicated by IgA vasculitis during therapy with tumor necrosis factor-α inhibitor;Hokama;Pol Arch Intern Med.,2019
4. IgA nephropathy in the setting of Anti-TNF-α therapy for inflammatory bowel disease;-Strobel;ACG Case Reports Journal,2020
5. Kidney Disease Improving Glocal Outcomes (KDIGO) clinical practice guideline for glomerulonephritis. Chapter 2: Immunoglobulin A nephropathy (IgAN)/immunoglobulin A vasculitis (IgAV);Kidney Int,2021